NPT-189 is under clinical development by Proclara Biosciences and currently in Phase I for Familial Amyloid Neuropathies. According to GlobalData, Phase I drugs for Familial Amyloid Neuropathies have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NPT-189’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NPT-189 is under development for the treatment of amyloid light chain (AL) and familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis). The drug candidate is a second generation candidate, composed of a fusion protein. It is administered through intravenous route. The drug candidate acts by targeting amyloid-beta (amyloid precursor protein), tau proteins, transthyretin and alpha-synuclein protein. The drug candidate is developed based on general amyloid interaction motif (GAIM) technology.
It was also under development for the treatment of alzheimer's disease.
Proclara Biosciences overview
Proclara Biosciences is a clinical-stage biotechnology company pioneering a breakthrough approach to treating neurodegenerative and peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins. The company is headquartered in Cambridge, Massachusetts, United States.
For a complete picture of NPT-189’s drug-specific PTSR and LoA scores, buy the report here.